New anticoagulants and regional anesthesia

Current Opinion in Anaesthesiology

Volumn 22, Issue 5, 2009, Pages 661-666

  Llau, Juan V ^a,b   Ferrandis, Raquel ^a,c  

^a Universitary Clinic Hospital   (Spain)

^b UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Anticoagulants; Dabigatran; Regional anesthesia; Rivaroxaban; Thromboprophylaxis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; ARGATROBAN; DABIGATRAN; DABIGATRAN ETEXILATE; HIRULOG; LEPIRUDIN; RIVAROXABAN;

BLEEDING; BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; EPIDURAL HEMATOMA; HUMAN; NERVE BLOCK; PERIPHERAL NERVE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REGIONAL ANESTHESIA; REVIEW; RISK ASSESSMENT; SPINAL HEMATOMA; STROKE; THROMBOCYTOPENIA;

EID: 70349153873     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32832eb8ab     Document Type: Review

References (33)

1. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs. Chest 2008; 133:234S-256S. This is one basic article to know and understand new anticoagulant drugs, reviewing the main concerns of all of them.
2. Gogarten W. The influence of new antithrombotic drugs on regional anesthesia. Curr Opin Anesthesiol 2006; 19:545-550.
3. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 2005; 105:453-463.
4. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Wkly 2009; 139:60-64.
5. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for thromboprophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28:1354-1373.
6. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet 2007; 370:949-956. (Pubitemid 47393577)
7. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5:2178-2185. (Pubitemid 47617868)
8. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrilation (PETRO study). Am J Cardiol 2007; 100:1419-1426.
9. Stangier J, Rathgen K, Staehle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64:292-303.
10. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353:1028-1040.
11. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48:1-22. In this paper, the authors review the pharmacological characteristics of new anticoagulants, and it should be read by anyone who wants to understand the differences between them
12. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765-2775.
13. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776-2786.
14. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939). Circulation 2007; 116:180-187.
15. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939 an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78:412-421.
16. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once and twice daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100:453-461.
17. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban: an oral direct factor Xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther 2007; 45:335-344.
18. Tryba M, Wedel DJ. Central neuraxial block and low molecular weight heparin (enoxaparin): lessons learned from different dosages regimes in two continents. Acta Anesthesiol Scand Suppl 1997; 111:100-104.
19. Schroeder DR. Statistics: detecting a rare adverse drug reaction using spontaneous reports. Reg Anesth Pain Med 1998; 23 (Suppl 2):183-189.
20. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004; 101:950-959.
21. Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal- epidural anesthesia. Anesth Analg 1994; 79:1165-1177.
22. Rosencher N, Bonnet MP, Sessler DI. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopedic surgery: management strategies. Anaesthesia 2007; 62:1154-1160. This article is, probably, the cornerstone to make recommendations for the practice of regional anesthesia in the setting of the use of anticoagulants. It is a marvellous article.
23. Wulf H. Epidural anaesthesia and spinal haematoma. Can J Anaesth 1996; 43:1260-1271.
24. Llau JV, De Andrés J, Gomar C, et al. Anticlotting drugs and regional anaesthetic and analgesic drugs: comparative update of safety recommendations. Eur J Anaesthesiol 2007; 24:387-394.
25. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006; 15:843-855.
26. Llau JV, López-Forte C, Sapena L, Ferrandis R. Perioperative management of antiplatelet agents in noncardiac surgery. Eur J Anaesth 2009; 26:181-187. Recent review for current practice in patients receiving antiplatelet agents in which the anesthesiologist wants to perform general or regional anesthesia.
27. Gogarten W, Van Aken H, Büttner J, et al. Regional anaesthesia and thromboembolism prophylaxis/anticoagulation: revised recommendations of the German Society for Anaesthesiology and Intensive Care. Anästh Intensivmed 2007; 48:S109-S124.
28. Kozek-Langenecker SA, Fries D, Gütl M, et al. Locoregional anesthesia and coagulation inhibitors. Anaesthetist 2005; 54:476-484.
29. Le Wendling L, Ennekin FK. Continuous peripheral nerve blockade for postoperative analgesia. Curr Opin Anesthesiol 2008; 21:602-609.
30. Capdevila X, Ponrouch M, Choquet O. Continuos peripheral nerve blocks in clinical practice. Curr Opin Anesthesiol 2008; 21:619-623.
31. Chin KJ, Chan V. Ultrasound guided peripheral nerve blockade. Curr Opin Anesthesiol 2008; 21:624-631.
32. Aveline C, Bonnet F. Delayed retroperitoneal haematoma after failed lumbar plexus block. Br J Anaesth 2004; 93:589-591.
33. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the Second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28:172-197.